Edition:
India

Syndax Pharmaceuticals Inc (SNDX.OQ)

SNDX.OQ on NASDAQ Stock Exchange Global Select Market

6.77USD
21 Sep 2018
Change (% chg)

$-0.38 (-5.31%)
Prev Close
$7.15
Open
$7.15
Day's High
$7.33
Day's Low
$6.50
Volume
181,975
Avg. Vol
84,203
52-wk High
$15.20
52-wk Low
$6.15

Chart for

About

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb... (more)

Overall

Beta: --
Market Cap(Mil.): $270.64
Shares Outstanding(Mil.): 22.22
Dividend: --
Yield (%): --

Financials

  SNDX.OQ Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -2.99 -- --
ROI: -42.86 15.07 14.61
ROE: -48.61 16.59 16.33

BRIEF-Syndax Pharmaceuticals Reports Q1 Loss Per Share $0.79

* SYNDAX PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CLINICAL AND BUSINESS UPDATE

09 May 2018

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $44.06 +0.31
Novartis AG (NOVN.S) CHF81.88 -0.06
Eli Lilly And Co (LLY.N) $106.33 +0.26

Earnings vs. Estimates